VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa ® agreement
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005914/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa® for the treatment of hyperkalemia in the People’s Republic of China. Under the agreement, Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China.
Stefan Schulze, CEO of Vifor Pharma Group comments, “We are delighted to expand VFMCRP’s collaboration with Fresenius Kabi. There is a high prevalence of CKD and heart failure in China3 and hyperkalemia is one of the most common complications associated with these two conditions. As a result there is a high demand for an effective, proven hyperkalemia treatment. The excellent commercial infrastructure, the well established relationships in nephrology and our existing successful collaboration make Fresenius Kabi our partner of choice to provide Veltassa® to patients.”
Oskar Haszonits, President Region Asia Pacific of Fresenius Kabi said, “This agreement is an important step in intensifying our collaboration and relationship with VFMCRP in nephrology. We believe Veltassa® has the potential to provide many benefits to patients across the country, and we look forward to adding it to our portfolio and working with VFMCRP.”
Hyperkalemia is a serious medical condition characterized by elevated levels of potassium in the blood and can be associated with life-threatening consequences. Patients with CKD and heart failure, especially those treated with RAAS (renin-angiotensin-aldosterone system) inhibitors are at particular risk of developing hyperkalemia. As a consequence, RAASi therapy, the cornerstone of treatment for CKD and heart failure, is often reduced or discontinued, compromising cardio-renal protection. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.
Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. In China, the company is among the top 10 multinational pharmaceutical companies, being a market leader in clinical nutrition, anesthesia and nephrology. Fresenius Kabi has around 6,000 employees in China.
Both parties have agreed to not disclose financial terms of the collaboration.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
For more information, please visit www.fresenius-kabi.com.
Approximately 73% of advanced Chronic Kidney Disease (CKD) and 40% of chronic heart failure patients may be at risk of elevated blood potassium levels4. Hyperkalemia can cause abnormal heart rhythms and even sudden death5. There are often no warning signs, meaning a person can unknowingly experience spikes in potassium levels recurrently and be at risk for these cardiac events. Some medicines that are often prescribed to people with CKD and heart failure to help delay progression of their underlying disease and reduce mortality can cause hyperkalemia as a side effect. These may include RAASi such as angiotensin receptor blockers (ARBs), aldosterone antagonists (AAs) and angiotensin converting-enzyme (ACE) inhibitors as well as angiotensin II receptor/neprilysin inhibitors (ARNI).
Veltassa® is a potassium binder approved for the treatment of hyperkalemia. Veltassa® was specially designed to exchange calcium rather than sodium for potassium ions, ensuring suitability for patients who cannot tolerate even small increases in sodium.Veltassa® should not replace emergency treatment for life-threatening hyperkalemia. Made in powder form, Veltassa® is mixed with water and taken once a day with or without food. Veltassa® is consisting of smooth, spherical, uniform microbeads too large to be absorbed, thus protecting the gastrointestinal tract. Veltassa® works primarily in the lumen of the colon where potassium concentration is highest, and the residence time of the polymer is the longest. The potassium is then excreted from the body through the normal excretion process.
1 Veltassa® EU SmPC 2019
2 Agarwal R, et al. Lancet 2019;394:1540–50.
3 Zhang et al. Lancet. 2012 Mar 3;379(9818):815-22; Guo et al. Int J Environ Res Public Health 2016; 13: E770. Guo et al. Curr Cardiol Rev. 2013 May; 9(2): 112–122.
4 Rosano GCM, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 2018;4:180-188.
5 Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J. 2001;77:759-764.
Global Head Corporate Communications
+41 79 957 96 73
Head of Investor Relations
+41 58 851 66 90
Fresenius SE & Co. KGaA
61352 Bad Homburg, Germany
+49 6172 60 82 115
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seglan Payments Solution Provider Turns to Verimatrix for Efficient, Time-Tested Security24.2.2021 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Seglan, an existing Verimatrix Code Protection customer and leading provider of secure payment solutions, recently selected the Verimatrix Mobile Payments technology to provide global banks and processors with time-trusted security. Seglan previously developed their own mobile payment Software Developer Kit (SDK) for implementation across its customer base. It’s now in the process of deploying Verimatrix’s mobile payments SDK that offers existing certifications for streamlining Seglan’s go-to-market capabilities aimed at some of the largest financial institutions in Europe and South America. The Verimatrix security tool will continue to be used for Seglan’s 3DSecure SDKs (certification included) while also aiming to provide their customers a full HCE and 3DSecure solution all contained within a single server. “Having successfully relied upon Ve
EnTrust Global’s Julian Proctor to Present at Economist’s World Ocean Summit24.2.2021 17:02:00 CET | Press release
Julian Proctor, Portfolio Manager of EnTrust Global’s Blue Ocean 4Impact Fund (“BO 4Impact”), will join Elisabeth Munck af Rosenschöld, Head of Supply Chain and Sustainability at IKEA, Sadan Kaptanoglu, President of BIMCO, Jeremy Nixon, Chief Executive of Ocean Network Express Co., and Craig Jasienski, Group Chief Executive at Wallenius Wilhelmsen at The Economist’ World Ocean Summit panel entitled “Shipping: Collaborating across industry and supply chains to reduce emissions.” Blue Ocean 4Impact is part of EnTrust Global’s $2+ billion maritime investment platform and is launching one of the first companies that will own and lease environmentally-advanced vessels and other marine infrastructure assets to large corporate operators and end-users, in order to help reduce carbon emissions and other pollution generated by the ocean economy. The Summit is the pre-eminent global event bringing together the widest cross-section of ocean stakeholders each year, from business to government to ci
New Study Finds Zio by iRhythm 10x More Effective in Proactively Identifying Atrial Fibrillation and Increasing Detection24.2.2021 17:00:00 CET | Press release
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand new “SCREEN-AF” study, led by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada and University Hospital in Leipzig, Germany, which was published in JAMA Cardiology. The transatlantic clinical trial found that Zio by iRhythm, an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care. One out of every 20 patients in the heart monitoring group was found to have a new diagnosis of atrial fibrillation and, as a result, 75 percent of those patients were subsequently prescribed a blood thinner medication for protection against strokes. The study results lend support for Zio as a screening tool for early detection of AF. The results have important implications for stroke prevention, especially as the pre
Jamestown Expands European Presence With More Than $1 Billion in Assets Under Management24.2.2021 16:22:00 CET | Press release
Global real estate and investment company Jamestown today announced it has significantly expanded its global presence and now has more than $1 billion in European assets under management with the acquisition of another two buildings in Amsterdam, and a mandate to manage a portfolio of properties across Europe on behalf of one of its institutional investment partners and co-investors, E.ON Pension Trust. This latest news about its European portfolio comes on the heels of Jamestown’s recent purchase of three office buildings in Cologne, Germany, and just over a year after purchasing the iconic Groot Handelsgebouw in Rotterdam, one of the largest mixed-use buildings in the Netherlands, which currently houses more than 450 businesses. “After entering the European market just over a year ago, Jamestown has grown its platform with $1 billion in assets under management and a knowledgeable real estate team headquartered in Cologne, Germany and offices in Amsterdam, London, and Madrid,” said Ja
Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansion24.2.2021 16:00:00 CET | Press release
Saint-Gobain Life Sciences, an industry leader in material science-based solutions for cell and gene therapy manufacturing, today launched a new cell culture bag designed specifically for T cell derived therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005014/en/ VueLife® "HP" Series Bag cell culture testing in Saint-Gobain Life Sciences Laboratory. (Photo: Business Wire) T cell based therapies are revolutionizing the approach to treating cancer. Harnessing the patient’s own immune system by isolating their T cells and engineering them to elicit an immune response is emerging as a preferred manufacturing practice. As the industry continues the advancement of these therapies, process efficiency becomes paramount to the success of delivering affordable therapies to patients. Building upon the VueLife® family of fluorinated ethylene propylene (FEP) based cell culture bags, VueLife® “HP” (high permeability) incorpo
KA Imaging to Present Poster on Unprecedented Lateral Dual-Energy X-ray Views at ECR 202124.2.2021 15:17:00 CET | Press release
KA Imaging, a company that develops innovative X-ray imaging solutions, announced that a poster reporting on results from a study examining the feasibility of lateral chest dual-energy subtraction radiography using a stacked single-exposure multi-layer x-ray detectorwill be presented by Sebastian Maurino, a medical physicist at KA Imaging, at this year’s European Congress of Radiology (ECR). As highlighted in the poster, KA Imaging’s novel approach allows radiologists to take full advantage of lateral dual-energy images by obtaining both conventional and dual-energy subtraction lateral images simultaneously, thereby making it considerably easier to differentiate between materials behind the heart. Quoting directly from the poster, “The DE lateral image also visualizes calcified joints and masses behind the heart that are not visible in the [Posterior-Anterior (PA)] image. Multi-layer detectors were shown to provide DE PA and lateral images of the chest at conventional patient dose leve
OAG and IATA Strengthen Data Partnership to Combat Market and Schedule Volatility24.2.2021 15:00:00 CET | Press release
OAG, the world’s leading provider of travel data and insight has agreed a partnership with International Air Transport Association (IATA), to provide schedule and reference data via its new cloud platform. As part of the strengthened partnership between the two aviation leaders, OAG will also provide IATA with a customized version of its market-leading Analyzer tool which will be offered as part of a bundle alongside Airport IS and other existing tools in the future. Built on the Snowflake cloud platform, the supply of reference and schedules data provides customers with the richest and freshest version of schedules data available in the market. “COVID-19’s ongoing impact on traffic volatility has made it critical to power our products with the most up-to-date data available,” said Charles de Gheldere, Director Aviation Data at IATA. “Our strengthened partnership with OAG supplies our airport customers with fresh and accurate data and a highly-innovative, modern and flexible cloud-base
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom